Language: JP/EN

研究業績

2024

  1. Ma Y, Okuda S, Okanishi H, Xu M, Jin C, Endou H, Ohgaki R, Kanai Y. Upregulation of ATF4 mediates the cellular adaptation to pharmacologic inhibition of amino acid transporter LAT1 in pancreatic ductal adenocarcinoma cells J Pharmacol Sci. 2024 Mar doi: 10.1097/RLU.0000000000004816.
  2. Chen S, Jin C, Ohgaki R, Xu M, Okanishi H, Kanai Y. Structure-activity characteristics of phenylalanine analogs selectively transported by L-type amino acid transporter 1 (LAT1). Sci Rep. 2024 Feb 26;14(1):4651. doi: 10.1038/s41598-024-55252-w.
  3. Liu X, Nishikubo K, Ohgaki R, Okanishi H, Okuda S, Xu M, Kanai Y. Identification of tumor-suppressive miRNAs that target amino acid transporter LAT1 and exhibit anti-proliferative effects on cholangiocarcinoma cells. J Pharmacol Sci. 2024 Apr;154(4):301-311. doi: 10.1016/j.jphs.2024.02.012. Epub 2024 Feb 24.
  4. Zhou X, Ohgaki R, Jin C, Xu M, Okanishi H, Endou H, Kanai Y. Inhibition of amino acid transporter LAT1 in cancer cells suppresses G0/G1-S transition by downregulating cyclin D1 via p38 MAPK activation. J Pharmacol Sci. 2024 Mar;154(3):182-191. doi: 10.1016/j.jphs.2024.01.007. Epub 2024 Jan 30.
  5. Rii J, Sakamoto S, Mizokami A, Xu M, Fujimoto A, Saito S, Koike H, Tamura T, Arai T, Yamada Y, Goto Y, Sazuka T, Imamura Y, Suzuki K, Kanai Y, Anzai N, Ichikawa T. L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity. Cancer Sci. 2023 Oct 1;48(10):853-860. doi: 10.1097/RLU.0000000000004816.

2023

  1. Alexander SPH, Fabbro D, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA, Amarosi L, Anderson CMH, Beart PM, Broer S, Dawson PA, Gyimesi G, Hagenbuch B, Hammond JR, Hancox JC, Hershfinkel M, Inui KI, Kanai Y, Kemp S, Kunji ERS, Stewart G, Tavoulari S, Thwaites DT, Verri T. The Concise Guide to PHARMACOLOGY 2023/24: Transporters. Br J Pharmacol. 2023 Oct;180 Suppl 2:S374-S469. doi: 10.1111/bph.16182.
  2. Zhang W, Miura A, Abu Saleh MM, Shimizu K, Mita Y, Tanida R, Hirako S, Shioda S, Gmyr V, Kerr-Conte J, Pattou F, Jin C, Kanai Y, Sasaki K, Minamino N, Sakoda H, Nakazato M.The NERP-4-SNAT2 axis regulates pancreatic b-cell maintenance and function. Nat Commun. 2023 Dec 9;14(1):8158. doi: 10.1038/s41467-023-43976-8.
  3. Watabe T, Ose N, Naka S, Fukui E, Kimura T, Kanou T, Funaki S, Sasaki H, Kamiya T, Kurimoto K, Isohashi K, Tatsumi M, Shimosegawa E, Kato H, Ohgaki R, Kanai Y, Shintani Y. Evaluation of LAT1 Expression in Patients With Lung Cancer and Mediastinal Tumors: 18F-FBPA PET Study With Immunohistological Comparison. Clin Nucl Med. 2023 Oct 1;48(10):853-860. doi: 10.1097/RLU.0000000000004816.
  4. Minoji T, Takahashi H, Watabe T, Ishikawa S, Kato H, Ohgaki R, Kanai Y, Sekido Y, Hata T, Hamabe A, Ogino T, Miyoshi N, Uemura M, Yamamoto H, Doki Y, Eguchi H. The Clinical Potential of FBPA-PET/CT Imaging for Colorectal Cancer and its Liver Metastases Expressing LAT1. Anticancer Res. 2023 Sep;43(9):3913-3921. doi: 10.21873/anticanres.16579.
  5. Shi Z, Kaneda-Nakashima K, Ohgaki R, Xu M, Okanishi H, Endou H, Nagamori S, Kanai Y. Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models. Sci Rep. 2023 Aug 25;13(1):13943. doi: 10.1038/s41598-023-41096-3.
  6. Nishikubo K, Ohgaki R, Liu X, Okanishi H, Xu M, Endou H, Kanai Y. Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells. Cancer Cell Int. 2023 Jun 15;23:116. doi: 10.1186/s12935-023-02957-z.
  7. Sui Y, Hoshi N, Ohgaki R, Kong L, Yoshida R, Okamoto N, Kinoshita M, Miyazaki H, Ku Y, Tokunaga E, Ito Y, Watanabe D, Ooi M, Shinohara M, Sasaki K, Zen Y, Kotani T, Matozaki T, Tian Z, Kanai Y, Kodama Y. LAT1 expression influences Paneth cell number and tumor development in ApcMin/+ mice. J Gastroenterol. 2023 Feb 15. doi: 10.1186/s40170-022-00295-8. Online ahead of print.

2022年

  1. Okanishi H, Ohgaki R, Xu M, Endou H, Kanai Y. Phosphoproteomics revealed cellular signals immediately responding to disruption of cancer amino acid homeostasis induced by inhibition of L-type amino acid transporter 1. Cancer Metab. 2022 Nov 10;10(1):18. doi: 10.1186/s40170-022-00295-8.
  2. Pae S, Sakamoto S, Zhao X, Saito S, Tamura T, Imamura Y, Sazuka T, Reien Y, Hirayama Y, Hashimoto H, Kanai Y, Ichikawa T, Anzai N. Targeting L-type amino acid transporter 1 in urological malignancy: Current status and future perspective. J Pharmacol Sci. 2022 Dec;150(4):251-258. doi: 10.1016/j.jphs.2022.10.002.
  3. Nakatani M, Nakahara SY, Fukui K, Urano M, Fujii Y, Murakawa T, Baba S, Kumasaka T, Okanishi H, Kanai Y, Yano T, Masui R. Crystal structure of a nucleotide-binding domain of fatty acid kinase FakA from Thermus thermophilus HB8. J Struct Biol. 2022 Oct 11;214(4):107904. doi: 10.1016/j.jsb.2022.107904.
  4. Nishikubo K, Ohgaki R, Okanishi H, Okuda S, Xu M, Endou H, Kanai Y. Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells. J Cell Mol Med. 2022 Sep. doi:10.1111/jcmm.17553.
  5. Kato T, Kusakizako T, Jin C, Zhou X, Ohgaki R, Quan L, Xu M, Okuda S, Kobayashi K, Yamashita K, Nishizawa T, Kanai Y, Nureki O. Structural insights into inhibitory mechanism of human excitatory amino acid transporter EAAT2. Nat Commun. 2022 Aug 11;13(1):4714. doi: 10.1038/s41467-022-32442-6.
  6. Ohtsu N, Ohgaki R, Jin C, Xu M, Okanishi H, Takahashi R, Matsui A, Kishimoto W, Ishiguro N, Kanai Y. Functional coupling of organic anion transporter OAT10 (SLC22A13) and monocarboxylate transporter MCT1 (SLC16A1) influencing the transport function of OAT10. J Pharmacol Sci. 2022 Jun 13;150(1):41-48. doi: 10.1016/j.jphs.2022.06.003.
  7. Sasaki S, Shiozaki Y, Hanazaki A, Koike M, Tanifuji K, Uga M, Kawahara K, Kaneko I, Kawamoto Y, Wiriyasermkul P, Hasegawa T, Amizuka N, Miyamoto KI, Nagamori S, Kanai Y, Segawa H. Tmem174, a regulator of phosphate transporter prevents hyperphosphatemia. Sci Rep. 2022 Apr 15;12(1):6353. doi: 10.1038/s41598-022-10409-3.
  8. Kurozumi S, Kaira K, Matsumoto H, Kurosumi M, Yokobori T, Kanai Y, Sekine C, Honda C, Katayama A, Furuya M, Shiino S, Makiguchi T, Mongan NP, Rakha EA, Oyama T, Fujii T, Shirabe K, Horiguchi J. Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. Sci Rep. 2022 Feb 17;12(1):2742. doi: 10.1038/s41598-022-06615-8.
  9. Hasegawa K, Ikeda S, Yaga M, Watanabe K, Urakawa R, Iehara A, Iwai M, Hashiguchi S, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Yoshihara S, Manabe M, Ichihara H, Mugitani A, Aoyama Y, Nakao T, Hirose A, Hino M, Ueda S, Takenaka K, Masuko T, Akashi K, Maruno T, Uchiyama S, Takamatsu S, Wada N, Morii E, Nagamori S, Motooka D, Kanai Y, Oji Y, Nakagawa T, Kijima N, Kishima H, Ikeda A, Ogino T, Shintani Y, Kubo T, Mihara E, Yusa K, Sugiyama H, Takagi J, Miyoshi E, Kumanogoh A, Hosen N. Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain. Sci Transl Med. 2022 Feb 16;14(632):eaax7706. doi: 10.1126/scitranslmed.aax7706.
  10. Kongpracha P, Wiriyasermkul P, Isozumi N, Moriyama S, Kanai Y, Nagamori S. Simple but efficacious enrichment of integral membrane proteins and their interactions for in-depth membrane proteomics. Mol Cell Proteomics. 2022 Jan 24:100206. doi: 10.1016/j.mcpro.2022.100206.

2021年

  1. Liu W, Wei L, Kanai Y, He X. Studies on the incompatibility between Bulbus fritillariae and Radix aconiti praeparata based on the P-gp. Evid Based Complement Alternat Med. 2021 Oct 5;2021:8351717. doi: 10.1155/2021/8351717.
  2. Alexander SP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Davies JA, Amarosi L, Anderson CMH, Beart PM, Broer S, Dawson PA, Hagenbuch B, Hammond JR, Inui KI, Kanai Y, Kemp S, Stewart G, Thwaites DT, Verri T. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters. Br J Pharmacol. 2021 Oct;178 Suppl 1:S412-S513. doi: 10.1111/bph.15543.
  3. Kanai Y. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacol Ther. 2021 Aug 11:107964. doi: 10.1016/j.pharmthera.2021.107964.
  4. Horita Y, Kaira K, Kawasaki T, Mihara Y, Sakuramoto S, Yamaguchi S, Okamoto K, Ryozawa S, Kanai Y, Yasuda M, Hamaguchi T. Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms. In Vivo. 2021 Jul-Aug;35(4):2425-2432. doi: 10.21873/invivo.12520.
  5. Maimaiti M, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Matsusaka K, Xu M, Ando K, Saito S, Wakai K, Imamura Y, Nakayama K, Kanai Y, Kaneda A, Ikehara Y, Ikeda JI, Anzai N, Ichikawa T. The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2. Sci Rep. 2021 Jun 1;11(1):11478. doi: 10.1038/s41598-021-90748-9.
  6. Rii J, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Yamada Y, Maimaiti M, Ando K, Wakai K, Xu M, Imamura Y, Shindo N, Hirota T, Kaneda A, Kanai Y, Ikehara Y, Anzai N, Tomohiko I. Functional analysis of LAT3 in prostate cancer: its downstream target and relationship with androgen receptor. Cancer Sci. 2021 May 29. doi: 10.1111/cas.14991. Online ahead of print.
  7. Kaneda-Nakashima K, Zhang Z, Manabe Y, Shimoyama A, Kabayama K, Watabe T, Kanai Y, Ooe K, Toyoshima A, Shirakami Y, Yoshimura T, Fukuda M, Hatazawa J, Nakano T, Fukase K, Shinohara A. α-Emitting cancer therapy using 211 At-AAMT targeting LAT1. Cancer Sci. 2021 Mar;112(3):1132-1140. doi: 10.1111/cas.14761.
  8. Okanishi H, Ohgaki R, Okuda S, Endou H, Kanai Y. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor. Cancer Sci. 2021 Feb;112(2):871-883. doi: 10.1111/cas.14756.
  9. Sato T, Furuta T, Liu Y, Naka S, Nagamori S, Kanai Y, Watabe T. Individual dosimetry system for targeted alpha therapy based on PHITS coupled with microdosimetric kinetic model. EJNMMI Phys. 2021 Jan 12;8(1):4. doi: 10.1186/s40658-020-00350-7.
  10. Fujino Y, Miyagawa T, Torii M, Inoue M, Fujii Y, Okanishi H, Kanai Y, Masui R. Structural changes induced by ligand-binding drastically increase the thermostability of the Ser/Thr protein kinase TpkD from Thermus thermophilus HB8. FEBS Lett. 2021 Jan;595(2):264-274. doi: 10.1002/1873-3468.13996.
  11. Sugiura M, Sato H, Okabe A, Fukuyo M, Mano Y, Shinohara KI, Rahmutulla B, Higuchi K, Maimaiti M, Kanesaka M, Imamura Y, Furihata T, Sakamoto S, Komiya A, Anzai N, Kanai Y, Luo J, Ichikawa T, Kaneda A. Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer. Transl Oncol. 2021 Jan;14(1):100915. doi: 10.1016/j.tranon.2020.100915.

2020年

  1. Quan L*, Ohgaki R*, Hara S, Okuda S, Wei L, Okanishi H, Nagamori S, Endou H, Kanai Y. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation. J Exp Clin Cancer Res. 2020 Nov 30;39(1):266. doi: 10.1186/s13046-020-01762-0. *Equal contribution
  2. Jimbo K*, Okuno T*, Ohgaki R*, Nishikubo K, Kitamura Y, Sakurai Y, Quan L, Shoji H, Kanai Y, Shimizu T, Yokomizo T. A novel mutation in the SLCO2A1 gene, encoding a prostaglandin transporter, induces chronic enteropathy. PLoS One. 2020 Nov 9;15(11):e0241869. doi: 10.1371/journal.pone.0241869. *Equal contribution
  3. Jin C, Wei L, Ohgaki R, Tominaga H, Xu M, Okuda S, Okanishi H, Kawamoto Y, He X, Nagamori S, Kanai Y. Interaction of halogenated tyrosine/phenylalanine-derivatives with Organic Anion Transporter (OAT) 1 in the renal handling of tumor imaging probes. J Pharmacol Exp Ther. 2020 Dec;375(3):451-462. doi: 10.1124/jpet.120.000235.
  4. Gyimesi G, Pujol-Gimenez J, Kanai Y, Hediger MA. Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application. Pflugers Arch. 2020 Sep;472(9):1177-1206. doi: 10.1007/s00424-020-02433-x.
  5. Hirai N, Watabe T, Nagamori S, Wiriyasermkul P, Tanaka Y, Romanov V, Naka S, Kanai Y, Liu Y, Tani N, Sakai T, Tatsumi M, Shimosegawa E, Kanai Y, Hatazawa J. Evaluation of D-isomer of 18F-FBPA for oncology PET focusing on the differentiation of glioma and inflammation. Asia Ocean J Nucl Med Biol. 2020 Spring;8(2):102-108. doi: 10.22038/AOJNMB.2020.47399.1321.
  6. Watabe T, Kaneda-Nakashima K, Shirakami Y, Liu Y, Ooe K, Teramoto T, Toyoshima A, Shimosegawa E, Nakano T, Kanai Y, Shinohara A, Hatazawa J. Targeted alpha therapy using astatine (211At)-labeled phenylalanine: A preclinical study in glioma bearing mice. Oncotarget. 2020 Apr 14;11(15):1388-1398. doi: 10.18632/oncotarget.27552.
  7. Hayashi K, Kaminuma O, Nishimura T, Saeki M, Matsuoka K, Hiroi T, Jutabha P, Iwata Y, Sugiura K, Owada T, Kurasawa K, Okayasu I, Ouchi M, Fujita T, Kanai Y, Endou H, Anzai N. LAT1-specific inhibitor is effective against T cell-mediated allergic skin inflammation. Allergy. 2020 Feb;75(2):463-467. doi: 10.1111/all.14019.
  8. Maimaiti M, Sakamoto S, Yamada Y, Sugiura M, Rii J, Takeuchi N, Imamura Y, Furihata T, Ando K, Higuchi K, Xu M, Sazuka T, Nakamura K, Kaneda A, Kanai Y, Kyprianou N, Ikehara Y, Anzai N, Ichikawa T. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma. Sci Rep. 2020 Jan 28;10(1):1292. doi: 10.1038/s41598-020-58136-x.

2019年

  1. Alexander SPH, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters. Br J Pharmacol. 2019 Dec;176 Suppl 1:S397-S493. doi: 10.1111/bph.14753.
  2. Jin C, Wu Z, Wang L, Kanai Y, He X. CYP450s-Activity Relations of Celastrol to Interact with Triptolide Reveal the Reasons of Hepatotoxicity of Tripterygium wilfordii. Molecules. 2019 Jun 8;24(11). pii: E2162.
  3. Ohgaki R, Teramura Y, Hayashi D, Nagamori S, Takai M, Kanai Y. [Cell surface pH imaging using poly(ethylene glycol)-phospholipid: its potential as the core structure of membrane anchored-probes]. Nihon Yakurigaku Zasshi. 2019;153(6):254-260. (Japanese)
  4. Lee Y, Wiriyasermkul P, Jin C, Quan L, Ohgaki R, Okuda S, Kusakizako T, Nishizawa T, Oda K, Ishitani R, Yokoyama T, Nakane T, Shirouzu M, Endou H, Nagamori S, Kanai Y, Nureki O. Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc. Nat Struct Mol Biol. 2019 Jun;26(6):510-517.
  5. Ogawa H, Kaira K, Motegi Y, Yokobori T, Takada T, Katoh R, Osone K, Takahashi R, Katayama C, Oyama T, Kanai Y, Yao T, Asao T, Kuwano H, Shirabe K. Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer. Anticancer Res. 2019 May;39(5):2535-2543.
  6. Miyabe J, Ohgaki R, Saito K, Wei L, Quan L, Jin C, Liu X, Okuda S, Nagamori S, Ohki H, Yoshino K, Inohara H, Kanai Y. Boron delivery for boron neutron capture therapy targeting a cancer-upregulated oligopeptide transporter. J Pharmacol Sci. 2019 Feb 18; pii: S1347-8613(19)30017-9.
  7. Aoki M, Watabe T, Nagamori S, Naka S, Ikeda H, Kongpracha P, Horitsugi G, Kanai Y, Shimosegawa E, Kanai Y, Hatazawa J. Distribution of LAT1-targeting PET tracer was independent of the tumor blood flow in rat xenograft models of C6 glioma and MIA PaCa-2. Ann Nucl Med. 2019 Feb 28; doi:10.1007/s12149-019-01346-9.
  8. Kaira K, Kawashima O, Endoh H, Imaizumi K, Goto Y, Kamiyoshihara M, Sugano M, Yamamoto R, Osaki T, Tanaka S, Fujita A, Imai H, Kogure Y, Seki Y, Shimizu K, Mogi A, Shitara Y, Oyama T, Kanai Y, Asao T. Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. Hum Pathol. 2019 Feb;84:142-149.

2018年

  1. Kandasamy P, Gyimesi G, Kanai Y, Hediger MA. Amino acid transporters revisited: New views in health and disease. Trends Biochem Sci. 2018 Aug pii: S0968-0004(18)30101-4.
  2. Weng L, Han YP, Enomoto A, Kitaura Y, Nagamori S, Kanai Y, Asai N, An J, Takagishi M, Asai M, Mii S, Masuko T, Shimomura Y, Takahashi M. Negative regulation of amino acid signaling by MAPK-regulated 4F2hc/Girdin complex. PLoS Biol. 2018 Mar 14;16(3):e2005090.
  3. Altan B, Kaira K, Watanabe A, Kubo N, Bao P, Dolgormaa G, Bilguun EO, Araki K, Kanai Y, Yokobori T, Oyama T, Nishiyama M, Kuwano H, Shirabe K.　Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.　Cancer Chemother Pharmacol. 2018 Jan;81(1):141-153.

2017年

  1. Ohgaki R, Teramura Y, Hayashi D, Quan L, Okuda S, Nagamori S, Takai M, Kanai Y.　Ratiometric fluorescence imaging of cell surface pH by poly(ethylene glycol)-phospholipid conjugated with fluorescein isothiocyanate.　Sci Rep. 2017 Dec 13;7(1):17484.
  2. Choi DW, Kim DK, Kanai Y, Wempe MF, Endou H, Kim JK.　JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells.　Korean J Physiol Pharmacol. 2017 Nov;21(6):599-607.
  3. Ikeda K, Kinoshita M, Kayama H, Nagamori S, Kongpracha P, Umemoto E, Okumura R, Kurakawa T, Murakami M, Mikami N, Shintani Y, Ueno S, Andou A, Ito M, Tsumura H, Yasutomo K, Ozono K, Takashima S, Sakaguchi S, Kanai Y, Takeda K.　Slc3a2 Mediates Branched-Chain Amino-Acid-Dependent Maintenance of Regulatory T Cells.　Cell Rep. 2017 Nov 14;21(7):1824-1838.
  4. Shinozaki Y, Furuichi K, Toyama T, Kitajima S, Hara A, Iwata Y, Sakai N, Shimizu M, Kaneko S, Isozumi N, Nagamori S, Kanai Y, Sugiura T, Kato Y, Wada T.　Impairment of the carnitine/organic cation transporter 1-ergothioneine axis is mediated by intestinal transporter dysfunction in chronic kidney disease.　Kidney Int. 2017 Dec;92(6):1356-1369.
  5. Honjo H, Toh Y, Sohda M, Suzuki S, Kaira K, Kanai Y, Nagamori S, Oyama T, Yokobori T, Miyazaki T, Kuwano H.　Clinical Significance and Phenotype of MTA1 Expression in Esophageal Squamous Cell Carcinoma.　Anticancer Res. 2017 Aug;37(8):4147-4155.
  6. Masuo Y, Nagamori S, Hasegawa A, Hayashi K, Isozumi N, Nakamichi N, Kanai Y, Kato Y.　Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans.　Pharm Res. 2017 Jun;34(6):1233-1243.
  7. Ohshima K, Nojima S, Tahara S, Kurashige M, Hori Y, Hagiwara K, Okuzaki D, Oki S, Wada N, Ikeda JI, Kanai Y, Morii E.　Argininosuccinate Synthase 1-Deficiency Enhances the Cell Sensitivity to Arginine through Decreased DEPTOR Expression in Endometrial Cancer.　Sci Rep. 2017 Mar 30;7:45504.
  8. Kume E, Mutou T, Kansaku N, Takahashi H, Wempe MF, Ikegami M, Kanai Y, Endou H, Wakui S.　Ultrastructural immunohistochemical study of L-type amino acid transporter 1-4F2 heavy chain in tumor microvasculatures of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) induced rat bladder carcinoma.　Microscopy (Oxf). 2017 Jun 1;66(3):198-203.
  9. Ohgaki R, Ohmori T, Hara S, Nakagomi S, Kanai-Azuma M, Kaneda-Nakashima K, Okuda S, Nagamori S, Kanai Y.　Essential Roles of L-Type Amino Acid Transporter 1 in Syncytiotrophoblast Development by Presenting Fusogenic 4F2hc.　Mol Cell Biol. 2017 May 16;37(11). pii: e00427-16.
  10. Kongpracha P, Nagamori S, Wiriyasermkul P, Tanaka Y, Kaneda K, Okuda S, Ohgaki R, Kanai Y.　Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1).　J Pharmacol Sci. 2017 Feb;133(2):96-102.
  11. Satoh T, Kaira K, Takahashi K, Takahashi N, Kanai Y, Asao T, Horiguchi J, Oyama T.　Prognostic Significance of the Expression of CD98 (4F2hc) in Gastric Cancer.　Anticancer Res. 2017 Feb;37(2):631-636. Erratum in: Anticancer Res. 2017 Mar;37(3):1539.
  12. Nagao H, Nishizawa H, Bamba T, Nakayama Y, Isozumi N, Nagamori S, Kanai Y, Tanaka Y, Kita S, Fukuda S, Funahashi T, Maeda N, Fukusaki E, Shimomura I.　Increased Dynamics of Tricarboxylic Acid Cycle and Glutamate Synthesis in Obese Adipose Tissue: IN VIVO METABOLIC TURNOVER ANALYSIS.　J Biol Chem. 2017 Mar 17;292(11):4469-4483.
  13. Watabe T, Ikeda H, Nagamori S, Wiriyasermkul P, Tanaka Y, Naka S, Kanai Y, Hagiwara K, Aoki M, Shimosegawa E, Kanai Y, Hatazawa J.　(18)F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with (18)F-FDG and (11)C-Methionine PET.　Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):321-331.

2016年

  1. Tarlungeanu DC, Deliu E, Dotter CP, Kara M, Janiesch PC, Scalise M, Galluccio M, Tesulov M, Morelli E, Sonmez FM, Bilguvar K, Ohgaki R, Kanai Y, Johansen A, Esharif S, Ben-Omran T, Topcu M, Schlessinger A, Indiveri C, Duncan KE, Caglayan AO, Gunel M, Gleeson JG, Novarino G.　Impaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder.　Cell. 2016 Dec 1;167(6):1481-1494.e18.
  2. Sakiyama M, Matsuo H, Nagamori S, Ling W, Kawamura Y, Nakayama A, Higashino T, Chiba T, Ichida K, Kanai Y, Shinomiya N.　Expression of a human NPT1/SLC17A1 missense variant which increases urate export.　Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):536-542.
  3. Ohshima Y, Kaira K, Yamaguchi A, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Yokobori T, Miyazaki T, Asao T, Tsushima Y, Kuwano H, Ishioka NS.　Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma.　Cancer Sci. 2016 Oct;107(10):1499-1505.
  4. Takamatsu S, Shimomura M, Kamada Y, Maeda H, Sobajima T, Hikita H, Iijima M, Okamoto Y, Misaki R, Fujiyama K, Nagamori S, Kanai Y, Takehara T, Ueda K, Kuroda S, Miyoshi E.　Core-fucosylation plays a pivotal role in hepatitis B pseudo virus infection: a possible implication for HBV glycotherapy.　Glycobiology. 2016 Nov;26(11):1180-1189.
  5. Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, Ueta K, Shiotani M, Nagamori S, Kanai Y.　Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.　J Pharmacol Exp Ther. 2016 Jul;358(1):94-102.
  6. Honjo H, Kaira K, Miyazaki T, Yokobori T, Kanai Y, Nagamori S, Oyama T, Asao T, Kuwano H.　Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma.　J Surg Oncol. 2016 Mar;113(4):381-9.
  7. Wei L, Tominaga H, Ohgaki R, Wiriyasermkul P, Hagiwara K, Okuda S, Kaira K, Kato Y, Oriuchi N, Nagamori S, Kanai Y.　Transport of 3-fluoro-L-α-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [(18)F]FAMT positron emission tomography.　J Pharmacol Sci. 2016 Feb;130(2):101-9.
  8. Wei L, Tominaga H, Ohgaki R, Wiriyasermkul P, Hagiwara K, Okuda S, Kaira K, Oriuchi N, Nagamori S, Kanai Y.　Specific transport of 3-fluoro-l-α-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging.　Cancer Sci. 2016 Mar;107(3):347-52.
  9. Nagamori S, Wiriyasermkul P, Guarch ME, Okuyama H, Nakagomi S, Tadagaki K, Nishinaka Y, Bodoy S, Takafuji K, Okuda S, Kurokawa J, Ohgaki R, Nunes V, Palacin M, Kanai Y.　Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1.　Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):775-80.
  10. Nagamori S, Wiriyasermkul P, Okuda S, Kojima N, Hari Y, Kiyonaka S, Mori Y, Tominaga H, Ohgaki R, Kanai Y.　Structure-activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling.　Amino Acids. 2016 Apr;48(4):1045-58.
  11. Xu M, Sakamoto S, Matsushima J, Kimura T, Ueda T, Mizokami A, Kanai Y, Ichikawa T.　Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.　J Urol. 2016 May;195(5):1588-97.
  12. Rosario FJ, Dimasuay KG, Kanai Y, Powell TL, Jansson T.　Regulation of amino acid transporter trafficking by mTORC1 in primary human trophoblast cells is mediated by the ubiquitin ligase Nedd4-2.　Clin Sci (Lond). 2016 Apr 1;130(7):499-512.
  13. Matsuo H, Yamamoto K, Nakaoka H, Nakayama A, Sakiyama M, Chiba T, Takahashi A, Nakamura T, Nakashima H, Takada Y, Danjoh I, Shimizu S, Abe J, Kawamura Y, Terashige S, Ogata H, Tatsukawa S, Yin G, Okada R, Morita E, Naito M, Tokumasu A, Onoue H, Iwaya K, Ito T, Takada T, Inoue K, Kato Y, Nakamura Y, Sakurai Y, Suzuki H, Kanai Y, Hosoya T, Hamajima N, Inoue I, Kubo M, Ichida K, Ooyama H, Shimizu T, Shinomiya N.　Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes.　Ann Rheum Dis. 2016 Apr;75(4):652-9.

2015年

  1. Furukawa J, Inoue K, Maeda J, Yasujima T, Ohta K, Kanai Y, Takada T, Matsuo H, Yuasa H.　Functional identification of SLC43A3 as an equilibrative nucleobase transporter involved in purine salvage in mammals.　Sci Rep. 2015 Oct 12;5:15057.
  2. Kaira K, Nakamura K, Hirakawa T, Imai H, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Tsukamoto N, Oyama T, Asao T, Minegishi T.　Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors.　Am J Transl Res. 2015 Jun 15;7(6):1161-71.
  3. Yazawa T, Shimizu K, Kaira K, Nagashima T, Ohtaki Y, Atsumi J, Obayashi K, Nagamori S, Kanai Y, Oyama T, Takeyoshi I.　Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma.　Am J Transl Res. 2015 Jun 15;7(6):1126-39.
  4. Shimizu A, Kaira K, Kato M, Yasuda M, Takahashi A, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Oyama T, Asao T, Ishikawa O.　Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma.　Melanoma Res. 2015 Oct;25(5):399-405.
  5. Rosario FJ, Kanai Y, Powell TL, Jansson T.　Increased placental nutrient transport in a novel mouse model of maternal obesity with fetal overgrowth.　Obesity (Silver Spring). 2015 Aug;23(8):1663-70.
  6. Koshi H, Sano T, Handa T, Yanagawa T, Saitou K, Nagamori S, Kanai Y, Takagishi K, Oyama T.　L-type amino acid transporter-1 and CD98 expression in bone and soft tissue tumors.　Pathol Int. 2015 Sep;65(9):460-7.
  7. Uetsuka S, Ogata G, Nagamori S, Isozumi N, Nin F, Yoshida T, Komune S, Kitahara T, Kikkawa Y, Inohara H, Kanai Y, Hibino H.　Molecular architecture of the stria vascularis membrane transport system, which is essential for physiological functions of the mammalian cochlea.　Eur J Neurosci. 2015 Aug;42(3):1984-2002.
  8. Gaccioli F, Aye IL, Roos S, Lager S, Ramirez VI, Kanai Y, Powell TL, Jansson T.　Expression and functional characterisation of System L amino acid transporters in the human term placenta.　Reprod Biol Endocrinol. 2015 Jun 9;13:57.
  9. Nikkuni O, Kaira K, Toyoda M, Shino M, Sakakura K, Takahashi K, Tominaga H, Oriuchi N, Suzuki M, Iijima M, Asao T, Nishiyama M, Nagamori S, Kanai Y, Oyama T, Chikamatsu K.　Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma.　Pathol Oncol Res. 2015 Sep;21(4):1175-81.
  10. Kaira K, Arakawa K, Shimizu K, Oriuchi N, Nagamori S, Kanai Y, Oyama T, Takeyoshi I.　Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer.　Am J Transl Res. 2015 Feb 15;7(2):356-63.
  11. Hanaoka H, Ohshima Y, Suzuki Y, Yamaguchi A, Watanabe S, Uehara T, Nagamori S, Kanai Y, Ishioka NS, Tsushima Y, Endo K, Arano Y.　Development of a Widely Usable Amino Acid Tracer: 76Br-α-Methyl-Phenylalanine for Tumor PET Imaging.　J Nucl Med. 2015 May;56(5):791-7.
  12. Wongthai P, Hagiwara K, Miyoshi Y, Wiriyasermkul P, Wei L, Ohgaki R, Kato I, Hamase K, Nagamori S, Kanai Y.　Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2.　Cancer Sci. 2015 Mar;106(3):279-86.
  13. Chiba T, Matsuo H, Kawamura Y, Nagamori S, Nishiyama T, Wei L, Nakayama A, Nakamura T, Sakiyama M, Takada T, Taketani Y, Suma S, Naito M, Oda T, Kumagai H, Moriyama Y, Ichida K, Shimizu T, Kanai Y, Shinomiya N.　NPT1/SLC17A1 is a renal urate exporter in humans and its common gain-of-function variant decreases the risk of renal underexcretion gout.　Arthritis Rheumatol. 2015 Jan;67(1):281-7.
  14. Toyoda M, Kaira K, Shino M, Sakakura K, Takahashi K, Takayasu Y, Tominaga H, Oriuchi N, Nikkuni O, Suzuki M, Iijima M, Tsukamoto N, Nagamori S, Kanai Y, Oyama T, Chikamatsu K.　CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma.　Head Neck. 2015 Nov;37(11):1569-74.
  15. Kaira K, Sunose Y, Arakawa K, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Oyama T, Takeyoshi I.　Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma.　Histopathology. 2015 Jan;66(2):234-43.

2014年

  1. Kaira K, Sunose Y, Oriuchi N, Kanai Y, Takeyoshi I. CD98 is a promising prognostic biomarker in biliary tract cancer.　Hepatobiliary Pancreat Dis Int.　2014 Dec;13(6):654-7.
  2. Namikawa M, Kakizaki S, Kaira K, Tojima H, Yamazaki Y, Horiguchi N, Sato K, Oriuchi N, Tominaga H, Sunose Y, Nagamori S, Kanai Y, Oyama T, Takeyoshi I, Yamada M.　Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma.　Hepatol Res. 2014 Oct 9.
  3. Isoda A, Kaira K, Iwashina M, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Oyama T, Asao T, Matsumoto M, Sawamura M.　Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma.　Cancer Sci. 2014 Nov;105(11):1496-502.
  4. Nagamori S, Kanai Y.　[Amino acid transporters in cancer].　Seikagaku. 2014 Jun;86(3):338-44. Review. Japanese.
  5. Chiba T, Matsuo H, Nagamori S, Nakayama A, Kawamura Y, Shimizu S, Sakiyama M, Hosoyamada M, Kawai S, Okada R, Hamajima N, Kanai Y, Shinomiya N.　Identification of a hypouricemia patient with SLC2A9 R380W, a pathogenic mutation for renal hypouricemia type 2.　Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):261-5.
  6. Yun DW, Lee SA, Park MG, Kim JS, Yu SK, Park MR, Kim SG, Oh JS, Kim CS, Kim HJ, Kim JS, Chun HS, Kanai Y, Endou H, Wempe MF, Kim DK.　JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells.　J Pharmacol Sci. 2014;124(2):208-17.
  7. Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, Sugiyama M, Tanaka Y, Kanai Y, Kusuhara H, Mizokami M, Wakita T.　Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).　Hepatology. 2014 May;59(5):1726-37.
  8. Kavitha JV, Rosario FJ, Nijland MJ, McDonald TJ, Wu G, Kanai Y, Powell TL, Nathanielsz PW, Jansson T.　Down-regulation of placental mTOR, insulin/IGF-I signaling, and nutrient transporters in response to maternal nutrient restriction in the baboon.　FASEB J. 2014 Mar;28(3):1294-305.
  9. Sakiyama M, Matsuo H, Shimizu S, Chiba T, Nakayama A, Takada Y, Nakamura T, Takada T, Morita E, Naito M, Wakai K, Inoue H, Tatsukawa S, Sato J, Shimono K, Makino T, Satoh T, Suzuki H, Kanai Y, Hamajima N, Sakurai Y, Ichida K, Shimizu T, Shinomiya N.　Common variant of leucine-rich repeat-containing 16A (LRRC16A) gene is associated with gout susceptibility.　Hum Cell. 2014 Jan;27(1):1-4.
  10. Matsuzaki S, Enomoto T, Serada S, Yoshino K, Nagamori S, Morimoto A, Yokoyama T, Kim A, Kimura T, Ueda Y, Fujita M, Fujimoto M, Kanai Y, Kimura T, Naka T.　Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.　Int J Cancer. 2014 Apr 15;134(8):1796-809.
  11. Oda A, Yamagata K, Nakagomi S, Uejima H, Wiriyasermkul P, Ohgaki R, Nagamori S, Kanai Y, Tanaka H.　Nicotine induces dendritic spine remodeling in cultured hippocampal neurons.　J Neurochem. 2014 Jan;128(2):246-55.
  12. Hatano R, Mukouchi H, Matsumoto Y, Kawaguchi K, Kazama I, Endo Y, Toyama H, Ejima Y, Kurosawa S, Kanai Y, Matsubara M, Asano S.　Glucocorticoid mediates the transcription of OAT-PG, a kidney-specific prostaglandin transporter.　Pflugers Arch. 2014 May;466(5):925-35.

2013年

  1. Segawa A, Nagamori S, Kanai Y, Masawa N, Oyama T.　L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer.　Mol Clin Oncol. 2013 Mar;1(2):274-280.
  2. Kaira K, Sunose Y, Ohshima Y, Ishioka NS, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, Kanai Y, Yamaguchi A, Segawa A, Ide M, Mori M, Oyama T, Takeyoshi I.　Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.　BMC Cancer. 2013 Oct 16;13:482.
  3. Mizuta I, Takafuji K, Ando Y, Satake W, Kanagawa M, Kobayashi K, Nagamori S, Shinohara T, Ito C, Yamamoto M, Hattori N, Murata M, Kanai Y, Murayama S, Nakagawa M, Toda T.　YY1 binds to α-synuclein 3'-flanking region SNP and stimulates antisense noncoding RNA expression.　J Hum Genet. 2013 Nov;58(11):711-9.
  4. Kazama I, Matsubara M, Kanai Y, Hatano R, Asano S, Endo Y, Toyama H, Ejima Y, Kurosawa S, Maruyama Y.　Decreased expression of a novel prostaglandin transporter, OAT-PG, facilitates renocortical PGE2 accumulation during rat pregnancy.　Gynecol Obstet Invest. 2013;76(3):163-70.
  5. Nobusawa A, Kim M, Kaira K, Miyashita G, Negishi A, Oriuchi N, Higuchi T, Tsushima Y, Kanai Y, Yokoo S, Oyama T.　Diagnostic usefulness of 1?F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma.　Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1692-700.
  6. Matsuo H, Ichida K, Takada T, Nakayama A, Nakashima H, Nakamura T, Kawamura Y, Takada Y, Yamamoto K, Inoue H, Oikawa Y, Naito M, Hishida A, Wakai K, Okada C, Shimizu S, Sakiyama M, Chiba T, Ogata H, Niwa K, Hosoyamada M, Mori A, Hamajima N, Suzuki H, Kanai Y, Sakurai Y, Hosoya T, Shimizu T, Shinomiya N.　Common dysfunctional variants in ABCG2 are a major cause of early-onset gout.　Sci Rep. 2013;3:2014.
  7. Kaira K, Toyoda M, Shino M, Sakakura K, Takahashi K, Tominaga H, Oriuchi N, Kanai Y, Oyama T, Chikamatsu K.　Clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with adenoid cystic carcinoma.　 Pathol Oncol Res. 2013 Oct;19(4):649-56.
  8. Fotiadis D, Kanai Y, Palacin M.　The SLC3 and SLC7 families of amino acid transporters.　Mol Aspects Med. 2013 Apr-Jun;34(2-3):139-58.
  9. Kanai Y, Clemencon B, Simonin A, Leuenberger M, Lochner M, Weisstanner M, Hediger MA.　The SLC1 high-affinity glutamate and neutral amino acid transporter family.　Mol Aspects Med. 2013 Apr-Jun;34(2-3):108-20.
  10. Ohshima Y, Hanaoka H, Tominaga H, Kanai Y, Kaira K, Yamaguchi A, Nagamori S, Oriuchi N, Tsushima Y, Endo K, Ishioka NS.　Biological evaluation of 3-[(18)F]fluoro-α-methyl-D-tyrosine (D-[(18)F]FAMT) as a novel amino acid tracer for positron emission tomography.　Ann Nucl Med. 2013 May;27(4):314-24.
  11. Bodoy S, Fotiadis D, Stoeger C, Kanai Y, Palacin M.　The small SLC43 family: facilitator system l amino acid transporters and the orphan EEG1.　Mol Aspects Med. 2013 Apr-Jun;34(2-3):638-45.
  12. Rosario FJ, Kanai Y, Powell TL, Jansson T.　Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells.　J Physiol. 2013 Feb 1;591(3):609-25.
2013年以前の業績についてはこちらをご参照ください(PubMedへリンク)